Compare Ascendis Pharma A/S (ASND) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Global Payments Inc — how do they compare? Ascendis Pharma A/S trades at $254.73 (market cap $16.67B), while Global Payments Inc trades at $85.39 (market cap $22.72B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays a 1.16% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GPN | |
|---|---|---|
Market Cap | $16.67B | $22.72B |
Sector | Health | Industrials |
52-Week High | $277.18 | $90.01 |
52-Week Low | $189.74 | $62.47 |
Enterprise Value | $17.04B | $40.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Global Payments (GPN) trades at $85.03, down 1.28% today, with a bullish technical signal from moving averages. Recent quarterly EPS beats and a consensus price target of $96.67 suggest upside potential, though negative net income margin and ROE highlight profitability challenges. Cash flow trends show strong operational performance, but rising debt-to-asset ratios warrant monitoring.
The outlook balances growth from Genius platform adoption against margin pressures and competitive fintech threats. Analysts are predominantly bullish, but investors should weigh earnings consistency against valuation risks and macroeconomic headwinds affecting payment volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
